沙美特罗替卡松吸入剂对稳定期COPD的疗效观察

Therapeutic effects of inhaling salmeterol-fluticasone in treatment of stable chronic obstructive pulmonary disease

目的观察中重度慢性阻塞性肺疾病(COPD)稳定期患者沙美特罗替卡松吸入剂临床疗效。方法 52例中重度COPD稳定期患者随机分为2组,治疗组(n=26)吸入沙美特罗替卡松。对照组(n=26)为空白对照组.不吸入沙美特罗替卡松。观察2组用药3月后肺功能的变化,St George’s呼吸问卷(SGRQ)调查,通过6min步行试验(6MWT)观察运动耐力的变化以及急性加重的人次、住院人次。结果用药3月后治疗组FEV1、最大肺活量(FVC)及FEVl/FVC比对照组明显改善,2组比较差异有显著性(P<0.05),治疗组SGRQ评分减少,运动耐力(6MWT)增加,随访3个月治疗组急性加重人次明显减少,与对照组比较差异有显著性(P<0.05)。结论吸入沙美特罗替卡松吸入剂可以改善稳定期中重度COPD患者肺功能与运动耐力,减少急性加重的发作,不良反应少,值得临床进一步推广。

Objective To observe the effects of therapy with inhaling of salmeterol-fluticasone in treatment of stable chronic obstructive pulmonary disease（COPD）.Methods Totally 52 patients with stable COPD were randomly divided into treatment and control groups.Baseline treatments were similar in all patients.24 patients in the treatment group received salmeterol-fluticasone inhalation twice a day for 3 months.The other 26 patients in the control group did not inhale salmeterol-fluticasone.Before and after the therapeutic course,tests for lung function in patients of these two groups were examined and compared with each other.The measures included the method of standard grade of respiratory diseases questionnaire（SGRQ）,6 minutes walk test（6MWT）,and the proportion of hospitalized patients due to AECOPD.Results The values of FEVl,FVC and FEVl/FVC in the treatment group increased in different extent than the control group（P0.05）.In the treatment group,the total scores of SGRQ decreased and 6MWT increased.In the teatment group,the proportion of hospitalized patients due to AECOPD was lower than that of the control group（P0.05）.Conclusions Salmeterol-fluticasone is effective on improving lung function and health status in patients with stable COPD.